FDA spells out details of corrective DTC advertising study


The FDA’s study of corrective direct-to-consumer (DTC) advertising will include 6,650 interviews of randomly assigned participants and include messaging about asthma in the first phase and weight-loss products in the second phase, according to a recent Federal Register notice covering the study’s information collection requirements. The agency is conducting the study to forward the development of empirical literature regarding the influences of corrective advertising. John Kamp, Executive Director, Coalition for Healthcare Communication, commented that this type of advertising “is an extraordinary remedy” that should be applied only to “violations that are extraordinary.” Read more.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR